NCT07167914View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

Health Participants

Interventions

DRUG

SFG-02

Transdermal Formulation (SFG-02)

DRUG

Placebo

Transdermal Formulation (Placebo)

Trial Locations (1)

Unknown

RECRUITING

Sumida Hospital, Tokyo

Sponsors

Lead Sponsor

Juro Sciences Inc.

All Listed Sponsors

lead

Juro Sciences Inc.

INDUSTRY

NCT07167914 - A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants | Biotech Hunter | Biotech Hunter